Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement

References

• The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135
   Google Scholar
• Ries L AG, Eisner M P, Kosary C L, Hankley B F, Milller B A, Clegg L, et al. SEER cancer statistics review, 1973 – 1999. National Cancer Institute, 2002. Bethesda, MD 2000, Available online at: http://seer.cancer.gov/csr/1973_1999/
   Google Scholar
• Horning S J, Rosenberg S A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311: 1471–1475
   PubMed Web of Science ®Google Scholar
• Groves F D, Linet M S, Travis L B, Devesa S S. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000; 92: 1240–1251
   PubMed Web of Science ®Google Scholar
• Johnson P W, Rohatiner A Z, Whelan J S, Price C G, Love S, Lim J, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13: 140–147
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez A J, Link B K, Levy R, Czucz M S, William M E, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Cheson B D. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003; 101: 391–398
   PubMed Web of Science ®Google Scholar
• Witzig T E, White C A, Wiseman G A, Gordon L I, Emmanouilde C, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793–3803
   PubMed Web of Science ®Google Scholar
• Vose J M, Wahl R L, Saleh M, Rohutiner A Z, Knox S J, Radford J A, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000; 18: 1316–1323
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Tuck M, Estes J, Kolstad A, Rossch, Zasadny, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441–449
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Zasadny K R, Francis I R, Milik A W, Ross C W, Moon S D, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14: 1974–1981
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Zasadny K R, Francis I R, Milik A W, Ross C W, Moon S D, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 459–465
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Zelenetz A D, Press O W, Saleh M, Leonard J, Feherenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19: 3918–3928
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Falndrin G, Muller–Hermelink H K, Vardiman J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 2000; 13: 193–207
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller–Hermelink H K, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10: 1419–1432
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller–Hermelink H K, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69–86
   PubMedGoogle Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller–Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Jaffe E S, Diebold J, Harris N L, Muller-Hermelink H K, Flandrin G, Vardiman J W. Burkitt's lymphoma: a single disease with multiple variants. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Blood 1999; 93: 1124
   PubMed Web of Science ®Google Scholar
• Jaffe E S, Harris N L, Diebold J, Muller-Hermelink H K. World Health Organization Classification of lymphomas: a work in progress. Ann Oncol 1998; 9(Suppl 5)S25–S30
   PubMedGoogle Scholar
• Jaffe E S, Harris N L, Diebold J, Muller-Hermelink H K. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 1999; 111(Suppl 1)S8–S12
   PubMed Web of Science ®Google Scholar
• Eisenhauer E A, O'Dwyer P J, Christian M, Humphrey J S. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000; 18: 684–692
   PubMed Web of Science ®Google Scholar
• Eary J F, Krohn K A, Press O W, Durack L, Bernstein I D. Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non-Hodgkin's lymphoma. Nucl Med Biol 1997; 24: 635–638
   PubMed Web of Science ®Google Scholar
• Eary J F, Pollard K R, Durack L D, Bice A N, Lewellen T K, Matthews D D, et al. Post therapy imaging in high dose I-131 radioimmunotherapy patients. Med Phys 1994; 21: 1157–1162
   PubMed Web of Science ®Google Scholar
• Hui T E, Fisher D R, Press O W, Eary J F, Weinstein JN J N, Badger CC C C, et al. Localized beta dosimetry of 131I-labeled antibodies in follicular lymphoma. Med Phys 1992; 19: 97–104
   PubMed Web of Science ®Google Scholar
• Press O W, Appelbaum F R, Eary J F, Bernstein I D. Radiolabeled antibody therapy of lymphomas. Important Adv Oncol 1995; 157–171
   PubMedGoogle Scholar
• Rajendran J G, Fisher D R, Gopal A K, Durack L D, Press O W, Eary J F. High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes. J Nucl Med 2004; 45: 1059–1064
   PubMed Web of Science ®Google Scholar
• Siegel J A. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy. J Nucl Med 1998; 39(8 Suppl)28S–33S
   PubMed Web of Science ®Google Scholar
• Siegel J A, Goldenberg D M, Badger C C. Radioimmunotherapy dose estimation in patients with B-cell lymphoma. Med Phys 1993; 20: 579–582
   PubMed Web of Science ®Google Scholar
• Siegel J A, Kroll S, Regan D, Kaminski M S, Wahl R L. A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy. J Nucl Med 2002; 43: 354–363
   PubMed Web of Science ®Google Scholar
• Cancer Therapy Evaluation Program. Common toxicity criteria, Version 2.0. DCTD, NCI, NIH, DHHS. 1999
   Google Scholar
• Leonard J P, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman R R, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 2005; 23: 5696–5704
   PubMed Web of Science ®Google Scholar
• Press O W, Unger J M, Braziel R M, Maloney D G, Miller T P, LeBlanc M, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: southwest Oncology Group Protocol S9911. Blood 2003; 102: 1606–1612
   PubMed Web of Science ®Google Scholar